1783 — Maxigen Biotech Cashflow Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesBalancedSmall CapHigh Flyer

Annual cashflow statement for Maxigen Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	97.5	166	193	226	305
Depreciation
Amortisation
Non-Cash Items	5.19	13.8	-30.7	-6.27	-39.4
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-18	59.2	-18.8	51.9	-7.37
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	118	268	171	298	290
Capital Expenditures	-15.4	-12	-19	-31.8	-82.6
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	12.7	22.4	-471	2.7	-300
Sale of Fixed Assets
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-2.77	10.4	-490	-29.1	-383
Financing Cash Flow Items	0.101	-0.101	0	0.542	4.7
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	189	-1.05	-41.4	-59.7	30.7
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	304	278	-360	208	-62.9